Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Draximage's BrachySeed pd-103 implant:

This article was originally published in Clinica

Executive Summary

Draximage has received US FDA 510(k) clearance to market its palladium-103 brachytherapy implant, BrachySeed Pd-103, for treating prostate cancer and other localised tumours, such as those of the breast, head, neck, lung, pancreas and uterus. Pending approval from the US Nuclear Regulatory Commission, the firm hopes to sell the product through its distribution partner Cytogen, later this year. Draximage, a subsidiary of Draxis Health (Mississauga, Ontario), already markets an iodine-125 BrachySeed implant in the US and Canada. It says it will be one of the few companies to offer both palladium and iodine implants.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel